James F III Oliviero
CIK 1434718 · CEO, President and Director · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.43M
Companies
3
Total Filings
67
Lifetime Open-Market Net
-$15.03M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVCT | Director | 122,828 | $19.82 | $2.43M | $0 | 5 | 2026-06-12 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | CEO, President and Director | 0 | $4.26 | $0 | -$4.34M | 22 | 2025-05-30 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Financial Officer | 209,406 | — | — | -$10.69M | 39 | 2015-07-08 |
Recent Filings · Page 3 of 7
67 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-04-05 | NVCT | Grant (A) | — | $0 | EDGAR |
| 2022-02-02 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +455,000 | $0 | EDGAR |
| 2021-02-05 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Sell (S) | −118,790 | -$412.3K | EDGAR |
| 2021-01-08 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +539,000 | $0 | EDGAR |
| 2020-02-25 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +598,000 | $0 | EDGAR |
| 2019-01-25 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +485,000 | $0 | EDGAR |
| 2018-02-01 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +325,000 | $0 | EDGAR |
| 2016-12-19 | — | Grant (A) | +325,000 | $0 | |
| 2015-07-08 | KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Sell (S) | −1,943 | -$18.7K | EDGAR |
| 2015-05-12 | KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Exer (M) | +41,611 | $111.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.